Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

10.7K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
10.7K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

735
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
735
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

290
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
290

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "A retrospective cohort study to examine the association between the persistence of abdominal pain after cholecystectomy and ejection fraction on HIDA scan in patients with biliary dyskinesia" [iLIVER 2 (2023) 208-213].

iLIVER·2026
Same author

A retrospective cohort study to examine the association between the persistence of abdominal pain after cholecystectomy and ejection fraction on HIDA scan in patients with biliary dyskinesia.

iLIVER·2025
Same author

The Emerging Role of Long Noncoding RNAs in Sorafenib Resistance Within Hepatocellular Carcinoma.

Cancers·2024
Same author

Fibrillary Glomerulonephritis Associated With Hashimoto's Thyroiditis.

Cureus·2024
Same author

A Unique Case of a Mildly Symptomatic Patient With Severe Hypokalemia Secondary to Furosemide.

Journal of investigative medicine high impact case reports·2024
Same author

Relevance of Procalcitonin Levels as a Marker of Severity and Predictor of Mortality, Initiation and Duration of Antibiotics in Patients Admitted with Acute Pancreatitis: A Retrospective Cohort Study.

Clinical and experimental gastroenterology·2024
Same journal

EXPRESS: Association between composite lipid indices (AIP, VAI, LAP) and Carotid Atherosclerosis with plaque: a Systematic review and Meta-analysis.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2026
Same journal

Meta-analysis of the clinical efficacy of microcatheter-assisted trabeculotomy in the treatment of glaucoma.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2026
Same journal

EXPRESS: The Association of Hidradenitis Suppurativa with Increased Risk of Systemic Infections in End-stage Renal Disease.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2026
Same journal

Artificial intelligence perceptions and experiences among first and second year medical students.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2026
Same journal

Effects of the glucagon-like peptide-1 and glucagon receptor dual agonists on glycemic markers: A systematic review and meta-analysis of randomized controlled trials.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2026
Same journal

EXPRESS: Enhancing clinical core competencies in postgraduate medical education: a comparative study of augmented reality-assisted and traditional teaching approaches.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2026
See all related articles

Related Experiment Video

Updated: Oct 11, 2025

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

13.6K

LECT-2 amyloidosis: what do we know?

Baldeep Kaur Mann1, Janpreet Singh Bhandohal2, Everardo Cobos3

  • 1Internal Medicine, Kern Medical Center, Bakersfield, California, USA baldeep.sippi@gmail.com.

Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research
|December 1, 2021
PubMed
Summary
This summary is machine-generated.

Amyloidosis, a rare disease of protein misfolding, includes a novel kidney-affecting form called ALECT2 amyloidosis. Diagnosis involves ruling out AL and AA types, aiding treatment decisions.

Keywords:
amyloidosischronickidney failure

More Related Videos

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

4.1K
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

10.8K

Related Experiment Videos

Last Updated: Oct 11, 2025

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

13.6K
Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

4.1K
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

10.8K

Area of Science:

  • Nephrology
  • Rare Diseases
  • Protein Misfolding Disorders

Background:

  • Amyloidosis involves abnormal protein folding and deposition.
  • Kidney involvement is common, leading to renal failure.
  • ALECT2 amyloidosis, a novel form, involves leukocyte chemotactic factor 2 (LECT-2).

Purpose of the Study:

  • To describe the characteristics of ALECT2 amyloidosis.
  • To differentiate ALECT2 from other amyloidosis types.
  • To highlight diagnostic approaches for ALECT2.

Main Methods:

  • Review of existing literature and case studies.
  • Analysis of clinical presentation and organ involvement.
  • Discussion of diagnostic criteria including immunohistochemistry and mass spectrometry.

Main Results:

  • ALECT2 amyloidosis primarily affects kidneys and liver.
  • Patients often present with minimal proteinuria and slightly elevated creatinine.
  • ALECT2 can co-occur with other conditions and may be misdiagnosed without specific testing.

Conclusions:

  • ALECT2 amyloidosis is a distinct entity requiring specific diagnostic consideration.
  • Suspect ALECT2 when AL and AA markers are negative.
  • Accurate diagnosis guides appropriate patient management and intervention.